Literature DB >> 31341054

Interferon-Inducible MicroRNA miR-128 Modulates HIV-1 Replication by Targeting TNPO3 mRNA.

Aurore Bochnakian1, Anjie Zhen2, Dimitrios G Zisoulis1, Adam Idica1, Vineet N KewalRamani3, Nicholas Neel2, Iben Daugaard1,4, Matthias Hamdorf1, Scott Kitchen2, KyeongEun Lee3, Irene Munk Pedersen5.   

Abstract

The HIV/AIDS pandemic remains an important threat to human health. We have recently demonstrated that a novel microRNA (miR), miR-128, represses retrotransposon long interspaced element 1 (L1) by a dual mechanism, namely, by directly targeting the coding region of the L1 RNA and by repressing a required nuclear import factor (TNPO1). We have further determined that miR-128 represses the expression of all three TNPO proteins (transportins TNPO1, TNPO2, and TNPO3). Here, we establish that miR-128 also influences HIV-1 replication by repressing TNPO3, a factor that regulates HIV-1 nuclear import and viral; replication of TNPO3 is well established to regulate HIV-1 nuclear import and viral replication. Here, we report that type I interferon (IFN)-inducible miR-128 directly targets two sites in the TNPO3 mRNA, significantly downregulating TNPO3 mRNA and protein expression levels. Challenging miR-modulated Jurkat cells or primary CD4+ T-cells with wild-type (WT), replication-competent HIV-1 demonstrated that miR-128 reduces viral replication and delays spreading of infection. Manipulation of miR-128 levels in HIV-1 target cell lines and in primary CD4+ T-cells by overexpression or knockdown showed that reduction of TNPO3 levels by miR-128 significantly affects HIV-1 replication but not murine leukemia virus (MLV) infection and that miR-128 modulation of HIV-1 replication is reduced with TNPO3-independent HIV-1 virus, suggesting that miR-128-indued TNPO3 repression contributes to the inhibition of HIV-1 replication. Finally, we determine that anti-miR-128 partly neutralizes the IFN-mediated block of HIV-1. Thus, we have established a novel role of miR-128 in antiviral defense in human cells, namely inhibiting HIV-1 replication by altering the cellular milieu through targeting factors that include TNPO3.IMPORTANCE HIV-1 is the causative agent of AIDS. During HIV-1 infection, type I interferons (IFNs) are induced, and their effectors limit HIV-1 replication at multiple steps in its life cycle. However, the cellular targets of INFs are still largely unknown. In this study, we identified the interferon-inducible microRNA (miR) miR-128, a novel antiviral mediator that suppresses the expression of the host gene TNPO3, which is known to modulate HIV-1 replication. Notably, we observe that anti-miR-128 partly neutralizes the IFN-mediated block of HIV-1. Elucidation of the mechanisms through which miR-128 impairs HIV-1 replication may provide novel candidates for the development of therapeutic interventions.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; TNPO3; interferons; miR-128; miRNA; nuclear import/export; restriction factor

Mesh:

Substances:

Year:  2019        PMID: 31341054      PMCID: PMC6798100          DOI: 10.1128/JVI.00364-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Models of HIV-1 persistence in the CD4+ T cell compartment: past, present and future.

Authors:  Mudit Tyagi; Fabio Romerio
Journal:  Curr HIV Res       Date:  2011-12-01       Impact factor: 1.581

Review 2.  New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites.

Authors:  Isidore Rigoutsos
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 3.  HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.

Authors:  Didier Trono; Carine Van Lint; Christine Rouzioux; Eric Verdin; Françoise Barré-Sinoussi; Tae-Wook Chun; Nicolas Chomont
Journal:  Science       Date:  2010-07-09       Impact factor: 47.728

4.  Flexible use of nuclear import pathways by HIV-1.

Authors:  KyeongEun Lee; Zandrea Ambrose; Thomas D Martin; Ilker Oztop; Alok Mulky; John G Julias; Nick Vandegraaff; Joerg G Baumann; Rui Wang; Wendy Yuen; Taichiro Takemura; Kenneth Shelton; Ichiro Taniuchi; Yuan Li; Joseph Sodroski; Dan R Littman; John M Coffin; Stephen H Hughes; Derya Unutmaz; Alan Engelman; Vineet N KewalRamani
Journal:  Cell Host Microbe       Date:  2010-03-18       Impact factor: 21.023

Review 5.  microRNA regulation of inflammatory responses.

Authors:  Ryan M O'Connell; Dinesh S Rao; David Baltimore
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

6.  Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha.

Authors:  Carolina Scagnolari; Pompea Zingariello; Jacopo Vecchiet; Carla Selvaggi; Delia Racciatti; Gloria Taliani; Elisabetta Riva; Eligio Pizzigallo; Guido Antonelli
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

7.  Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus.

Authors:  Alberto De Iaco; Jeremy Luban
Journal:  Retrovirology       Date:  2011-12-06       Impact factor: 4.602

8.  miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells.

Authors:  I Daugaard; K J Sanders; A Idica; K Vittayarukskul; M Hamdorf; J D Krog; R Chow; D Jury; L L Hansen; H Hager; P Lamy; C L Choi; D Agalliu; D G Zisoulis; I M Pedersen
Journal:  Oncogenesis       Date:  2017-07-31       Impact factor: 7.485

Review 9.  MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes.

Authors:  Karen Chiang; Andrew P Rice
Journal:  Viruses       Date:  2012-08-29       Impact factor: 5.048

10.  The Role of TNPO3 in HIV-1 Replication.

Authors:  Felipe Diaz-Griffero
Journal:  Mol Biol Int       Date:  2012-07-19
View more
  7 in total

1.  HIV-infection and cocaine use regulate semen extracellular vesicles proteome and miRNAome in a manner that mediates strategic monocyte haptotaxis governed by miR-128 network.

Authors:  Hussein Kaddour; Steven Kopcho; Yuan Lyu; Nadia Shouman; Victor Paromov; Siddharth Pratap; Chandravanu Dash; Eun-Young Kim; Jeremy Martinson; Heather McKay; Marta Epeldegui; Joseph B Margolick; Jack T Stapleton; Chioma M Okeoma
Journal:  Cell Mol Life Sci       Date:  2021-12-22       Impact factor: 9.207

2.  Transportin-3 Facilitates Uncoating of Influenza A Virus.

Authors:  Jiahui Zou; Luyao Yu; Yinxing Zhu; Shuaike Yang; Jiachang Zhao; Yaxin Zhao; Meijun Jiang; Shengsong Xie; Hailong Liu; Changzhi Zhao; Hongbo Zhou
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

Review 3.  Interaction Between Non-Coding RNAs and Interferons: With an Especial Focus on Type I Interferons.

Authors:  Soudeh Ghafouri-Fard; Yadollah Poornajaf; Farzaneh Dashti; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

4.  MicroRNAs and exosomes: key players in HIV pathogenesis.

Authors:  J Sadri Nahand; F Bokharaei-Salim; M Karimzadeh; M Moghoofei; S Karampoor; H R Mirzaei; A Tabibzadeh; A Jafari; A Ghaderi; Z Asemi; H Mirzaei; M R Hamblin
Journal:  HIV Med       Date:  2019-11-22       Impact factor: 3.180

Review 5.  MicroRNA-1: Diverse role of a small player in multiple cancers.

Authors:  Parvez Khan; Nivetha Sarah Ebenezer; Jawed Akhtar Siddiqui; Shailendra Kumar Maurya; Imayavaramban Lakshmanan; Ravi Salgia; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Semin Cell Dev Biol       Date:  2021-05-24       Impact factor: 7.727

Review 6.  Role of Transportin-SR2 in HIV-1 Nuclear Import.

Authors:  Maryam Tabasi; Ivan Nombela; Julie Janssens; Adrien P Lahousse; Frauke Christ; Zeger Debyser
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.048

Review 7.  The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.

Authors:  Jiulue Hu; Jelena Stojanović; Saman Yasamineh; Pooneh Yasamineh; Sathish Kumar Karuppannan; Mohammed Junaid Hussain Dowlath; Hamed Serati-Nouri
Journal:  Arch Virol       Date:  2021-07-19       Impact factor: 2.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.